Warther Private Wealth LLC Sells 4,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Warther Private Wealth LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 90.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 464 shares of the biopharmaceutical company’s stock after selling 4,200 shares during the period. Warther Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $294,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. Traphagen Investment Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 11.9% in the first quarter. Traphagen Investment Advisors LLC now owns 770 shares of the biopharmaceutical company’s stock worth $488,000 after acquiring an additional 82 shares during the last quarter. Asio Capital LLC boosted its holdings in Regeneron Pharmaceuticals by 13.6% in the 1st quarter. Asio Capital LLC now owns 3,995 shares of the biopharmaceutical company’s stock valued at $2,534,000 after purchasing an additional 477 shares during the period. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 5.8% in the 1st quarter. Brighton Jones LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $636,000 after purchasing an additional 55 shares during the period. Factory Mutual Insurance Co. grew its position in Regeneron Pharmaceuticals by 210.3% in the 1st quarter. Factory Mutual Insurance Co. now owns 12,100 shares of the biopharmaceutical company’s stock worth $7,674,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Ritholtz Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 7.8% during the 1st quarter. Ritholtz Wealth Management now owns 486 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 35 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. UBS Group cut their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a research note on Thursday, June 5th. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, June 2nd. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $529.24 on Monday. The business has a fifty day moving average of $563.19 and a 200-day moving average of $648.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The firm has a market cap of $57.14 billion, a PE ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business posted $9.55 EPS. The company’s revenue was down 3.7% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.